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accompanied by an increase in IL-8 mRNA expression and 
a dose- and time-dependent release of IL-8. Cellular prolif-
eration as well as the release of IL-8 was dependent on spe-
cific ligation of TLR-2. Interestingly, targeting IL-8 by neu-
tralizing antibodies completely abolished the LTA-induced 
proliferation of A549 cells. The pro-proliferative effect of 
LTA could also be reproduced in the squamous NSCLC 
cell line H226. In summary, LTA of S. aureus induced pro-
liferation of NSCLC cell lines of adeno- and squamous cell 
carcinoma origin. Ligation of TLR-2 followed by auto- or 
paracrine signalling by endogenously synthesized IL-8 is 
centrally involved in LTA-induced tumor cell proliferation. 
Therefore, pulmonary infections may exert a direct pro-pro-
liferative effect on lung cancer growth.
Keywords Lung cancer · Infection · Lipoteichoic acids · 
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Abbreviations
DSMZ  Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH
Lpp  Lipopeptides
LTA  Lipoteichoic acids
MTS  3-(4, 5-Dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium
NSCLC  Non-small-cell lung cancer
S. aureus  Staphylococcus aureus
STR  Short-tandem repeat
Introduction
Lung cancer is the leading cause of cancer-related death in 
the western hemisphere [1]. In the course of the disease, 
Abstract Pulmonary infections are frequent complica-
tions in lung cancer and may worsen its outcome and sur-
vival. Inflammatory mediators are suspected to promote 
tumor growth in non-small-cell lung cancer (NSCLC). 
Hence, bacterial pathogens may affect lung cancer growth 
by activation of inflammatory signalling. Against this back-
ground, we investigated the effect of purified lipoteichoic 
acids (LTA) of Staphylococcus aureus (S. aureus) on cel-
lular proliferation and liberation of interleukin (IL)-8 in 
the NSCLC cell lines A549 and H226. A549 as well as 
H226 cells constitutively expressed TLR-2 mRNA. Even 
in low concentrations, LTA induced a prominent increase 
in cellular proliferation of A549 cells as quantified by 
automatic cell counting. In parallel, metabolic activity of 
A549 cells was enhanced. The increase in proliferation was 
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patients frequently develop pulmonary infections which 
have been reported to reduce the median survival substan-
tially [2]. It is not clear, whether this reduction in median 
survival is merely attributable to the clinical complications 
of pulmonary infections, or whether bacteria may directly 
stimulate lung cancer growth.
Although the most common pathogens found in NSCLC 
are of Gram-negative origin, Gram-positive germs such as 
Staphylococcus aureus (S. aureus) and Streptococcus pneu-
moniae account for about 25% of pulmonary infections in 
lung cancer patients and are the leading cause of septicemia 
in lung cancer [3]. Cell wall components of bacterial patho-
gens such as lipopolysaccharides, the so-called “endotoxin” 
of Gram-negative bacteria and their Gram-positive equiva-
lents, lipoteichoic acids (LTA), peptidoglycanes and lipo-
peptides (Lpp) [4] are major bacterial pathogenicity factors. 
After ligation of LPS to the CD14 molecule [5], cellular 
activation is initiated by binding to toll-like receptors. It 
is widely accepted that TLR-4 confers responsiveness to 
LPS [6, 7] while TLR-2 seems to be the key receptor for 
LTA [8–10]. Once TLR-dependent signalling is initiated, 
a plethora of proinflammatory mediators such as cytokines 
and lipid mediators are released by immunocompetent cells 
[8, 11].
It is well established that persistent inflammation and 
inflammatory mediators can promote cancer growth 
[12–14]. In lung cancer, a clear pathogenic role has been 
attributed to chronic inflammatory diseases such as chronic 
obstructive pulmonary disease [15]. One early step in the 
development of lung cancer is the activation of inflam-
matory cascades resulting in synthesis of growth factors 
and cytokines such as TGF-ß, IL-1, and IL-8 [15]. Once 
lung cancer has developed, further tumor progression 
may be caused by inflammatory mediators [16]. Among 
these inflammatory mediators IL-8 is of special relevance, 
because in cultured NSCLC cells and in animal models of 
NSCLC IL-8 has been shown to promote tumor growth 
[17, 18]. Moreover, in lung cancer patients, there is a clear 
correlation between IL-8 expression, tumor angiogenesis 
and overall survival [19].
Synthesis of IL-8 is induced in response to activation 
of TLRs in myeloid-derived cells such as macrophages 
and neutrophils [20, 21]. Interestingly, the expression of 
TLRs is not restricted to myeloid-derived cells. As TLRs 
are found in a variety of human cancers of epithelial ori-
gin, they could definitively play a role in cancer progres-
sion. In gastric cancer, the expression of different TLRs 
enables gastric carcinoma cells to interact with Helico-
bacter pylori [22], which is followed by the production 
of tumor-promoting factors such as IL-8 [23] and pro-
liferation of cancer cells [24]. Remarkably, an up-regu-
lation of TLR-4 expression was recently demonstrated in 
human adenocarcinoma of the lung in  vivo and TLR-4 
expression levels correlated with malignancy [25]. TLR-2 
is equally expressed by NSCLC cells in  vitro [26] and 
TLR-2 mRNA has been detected in the bronchoalveolar 
fluid of patients with NSCLC [27].
Thus, specific interactions between bacterial patho-
gens and tumor cells may actually occur in NSCLC. For 
LPS, enhancement of lung cancer tumor growth has been 
described in NSCLC cell lines and in xenograft and in 
orthotopic models of lung cancer [28, 29]. In contrast, 
the consequences of the interaction between lung cancer 
cells and LTA are less obvious.
In the current study, we investigated the effect of 
highly purified LTA from S. aureus on proliferation 
and metabolic activity in human NSCLC cell lines of 
adeno- and squamous cell carcinoma origin. In essence, 
we found that LTA is a pro-proliferative stimulus for the 
tumor cell lines. Cellular activation proceeded via liga-
tion of TLR-2 and endogenously formed IL-8 turned out 




The human lung adenocarcinoma cell line A549 (ATCC-
CCL-185) as well as the human lung squamous carci-
noma cell line H226 were obtained from the American 
Type Culture Collection (Rockville, MD, USA) and cul-
tured at 37 °C in a humidified atmosphere (95% air, 5% 
 CO2). Cells were used up to passage 40. Cells were regu-
larly checked for contamination with mycoplasma by the 
local department of microbiology by analysis of 16S r 
DNA followed by amplicon sequencing as previously 
described [30, 31]. Moreover, both cell lines used were 
subjected to authentication by the German Collection of 
Microorganisms and Cell Cultures (“Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH”, DSMZ) 
by short-tandem repeat (STR) DNA profiling [32]. STR 
profiles of the currently used cell lines showed a full 
match with the respective reference STR profiles. Thus, 
the A549 and H226 cells used in the current study were 
derived from authentic cell cultures. All cell culture 
media and supplements were from Gibco (Eggenstein, 
Germany), and cell culture plasticware was from Greiner 
Bio-One (Frickenhausen, Germany). NSCLC cell lines 
were grown in Dulbecco’s modified Eagle’s medium 
(DMEM/F12), supplemented with 10% FCS, 2  mM 
l-glutamine,  105 U/l penicillin and 100  mg/l streptomy-
cin (culture medium). Cells were grown to confluence 
and subcultured every 2–3 days at a split ratio of 1:10.
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Assessment of cellular proliferation by cell counting
A549 or H226 cells were seeded on 24-well plates (15,000 
cells/well for A549 and 30,000 cells/well for H226) and 
maintained in culture medium for 24 h before stimulation 
with LTA (S. aureus, purified, InvivoGen, San Diego, CA, 
USA) After removement of culture medium by two wash-
ing procedures with RPMI, cells were kept in DMEM/F12 
supplemented with 1% FCS at a total volume of 500  µl/
well. NSCLC cells were exposed to various concentrations 
of LTA or sham-incubation was performed (control). In an 
additional series of experiments in Fig. 4, function-block-
ing antibodies targeting TLR-2 (clone TL2.1, e-Bioscience, 
San Diego, CA, USA), TLR-4 (clone HTA 125, e-Biosci-
ence, San Diego, CA, USA), or IL-8 (MAB 208, R&D 
Systems, Wiesbaden, Germany) were applied simultane-
ously to LTA. Antibodies targeting TLRs were applied at 
0.5 µg/ml, whereas the neutralizing IL-8 antibody was used 
at 5 µg/ml. At the end of the incubation period from 24 to 
72 h, medium was removed, cells were washed twice and 
subsequently treated with 0.5% trypsin–EDTA. Detached 
cells were resuspended in a stop-solution (PBS containing 
20% FCS) and subsequently counted automatically by the 
cell counter-analyzer system CasyR Model TT (Innovatis 
AG, Reutlingen, Germany). Data were expressed as per-
centage of controls (sham-incubated cells), which were set 
to 100%. Two technical replicates per sample were run in 
each independent experiment.
MTS assay
The MTS assay (CellTiter 96@ Aqueous One Solution 
Cell Proliferation Assay, Promega, Mannheim, Germany) 
quantifies the metabolic activity of cells. This assay is 
used to quantify cellular proliferation and is based upon 
the cleavage of the yellow 3-(4, 5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium, inner salt (MTS) to purple formazan by metabolic 
active cells. A549 or H226 cells were seeded on 96-well 
plates (2500 cells/well for A549 and 5000 cells for H226) 
24 h before stimulation with LTA in culture medium. After 
removement of culture medium and two washing proce-
dures, cells were kept in DMEM/F12 supplemented with 
1% FCS at a total volume of 200  µl/well. Both NSCLC 
cell lines were stimulated with increasing concentrations 
of LTA for various time periods; alternatively, sham-incu-
bated controls were run for each time period. 2.5 h before 
the end of the incubation period, 20  µl of MTS solution 
were added to each well and plates were incubated for 
another 2.5 h under light protection and continuous shak-
ing. Then, absorbance was read at 490  nm, background 
readings were subtracted from the sample wells and data 
were expressed as percentage of controls (sham-incubated 
cells) which were set to 100%. Five technical replicates per 
sample were run in each independent experiment.
Measurement of IL-8
IL-8 was quantified from the cell supernatants of LTA-
stimulated A549 cells by ELISA technique. For these 
experiments, A549 cells (15,000 cells/well) were seeded 
on 24-well plates and grown to confluence. Confluent mon-
olayers were washed twice and kept in DMEM/F12 with 1% 
FCS at a total volume of 500 µl/well. Then, incubation with 
different concentrations of LTA or sham-incubation (con-
trol) was performed for various time periods. In a separate 
set of experiments, stimulation with LTA was performed in 
the absence or presence of antibodies targeting TLR-2 and 
TLR-4. Two technical replicates per sample were run in 
each independent experiment. At the end of the incubation 
period, cell supernatants were harvested, cell debris was 
removed by centrifugation at 13.000×g and samples were 
stored at −20 °C until further processing. Release of IL-8 
was determined in a direct sandwich ELISA, as described 
previously [33]. To normalize the data, IL-8 was expressed 
as ΔIL-8, meaning that baseline levels of IL-8 secreted 
from unstimulated controls were subtracted from those 
induced by stimulation with LTA.
RNA isolation and real-time RT-PCR
For quantification of IL-8 mRNA, experiments with A549 
cells (50,000 cells/well) were performed as described 
above. Each independent experiment consisted of two tech-
nical replicates per sample.
Total RNA was extracted from cells with TRIzol Rea-
gent (Invitrogen, Karlsruhe, Germany) according to the 
manufacturer’s protocols. Extracted RNA was quantified 
with Nano Drop (PeqLab, Erlangen, Germany). Residual 
DNA was digested with DNase (Invitrogen, Karlsruhe, 
Germany) and cDNA was synthesized by RT (Bio-Rad, 
München, Germany). Real-time PCR was performed using 
1 μg of cDNA, SYBR Green PCR Master Mix (Bio-Rad, 
München, Germany) and 0.05  M forward/reverse prim-
ers; specific primers used for sequence detection were as 
follows:
for IL-8:
5′AGT TTT GCC AAG GAG TGC TAAA3′ (forward) and 
5′TGA ATT CTC AGC CCT CTT CAAA3′ (reverse).
for PBGD:
5′CAG CTT GCT CGC ATA CAG AC3′ (forward) and 
5′GAA TCT TGT CCC CTG TGG TG3′ (reverse).
for TLR2:
5′AGC CTT GAC CTG TCC AAC AA3′ (forward) and 
5′GGC TTG AAC CAG GAA GAC GA3′ (reverse).
 Cancer Immunol Immunother
1 3
Real-time-reactions were carried out on the CFX 
Connect Real-Time PCR Detection System (Bio-Rad, 
München, Germany) with following cycle conditions: 
denaturation at 95 °C for 3 min; 40 cycles with denatur-
ation at 95 °C for 10  s, annealing at 59 °C for 10  s and 
extension at 72 °C for 10  s. To ensure single-product 
amplification, a dissociation curve was generated for each 
gene and the threshold cycle (Ct values) for each gene 
was determined.
Relative mRNA-levels were expressed as ΔCt val-
ues which were calculated with the genes Ct values 
normalized to the housekeeping gene PBGD Ct values. 
The comparative 2^ΔΔCt method was used to analyze 
mRNA-fold changes between control and LTA, which 
was calculated as ratio = 2^(ΔCt control−ΔCt LTA) [28, 
34]. Ct is the cycle threshold and ΔCt (Ct gene of inter-
est−Ct housekeeping gene) is the CT value normalized 
to the housekeeping gene PBGD obtained for the same 
cDNA samples. The specificity of the primer pair prod-
ucts was tested by agarose (1.5%) gel electrophoresis 
(Supplementary Fig. 1).
Statistics
Unlike otherwise indicated, data are given as the rela-
tive changes compared to control values and expressed as 
the mean ± SEM. Data analysis was performed in R [35] 
using the packages “lme4” and “lmerTest” [36]. Data were 
analyzed with linear mixed models to account for inter-
experimental differences. The variable “time” was taken as 
a factor in a two-factorial model together with “LTA con-
centration”. Data were checked for the agreement with the 
model assumptions by analysis of the residuals. MTS activ-
ity data were inversely transformed before statistical analy-
sis to meet the model assumptions. The diagrams show the 
means with SEM. The horizontal dashed line indicates the 
value of the unstimulated controls. For statistical analy-
sis of changes in mRNA expression, student´s t test was 
performed. Groups or conditions with p < 0.05 are marked 
with asterisks.
Results
A549 and H226 cells express TLR-2 mRNA
To confirm that the NSCLC cell lines used express TLR-2 
as a prerequisite for specific interaction with LTA, we ana-
lyzed TLR-2 mRNA by PCR. PDGD served as housekeep-
ing gene. Unstimulated A549 and H226 cells were clearly 
positive for TLR-2 mRNA, as depicted in Table 1a. Inter-
estingly, upon treatment with 0.1  µg/ml LTA for 24  h, 
TLR-2 expression was doubled in A549 cells, whereas 
H226 cells did not show any up-regulation of TLR-2 
mRNA after stimulation with LTA (Table 1b). Specificity 
of the primer pairs was visualized by agarose (1.5%) gel 
electrophoresis (Supplementary Fig. 1).
LTA induces proliferation of A549 cells
A549 cells were stimulated with different concentrations of 
LTA (0.01–1 µg/ml) for various time periods (24, 48, 72 h) 
or sham-incubation was performed (baseline). The highly 
purified LTA preparation stimulated the proliferation of 
A549 cells in a time-dependent manner, as quantified by 
automatic cell counting (Fig. 1a). LTA-induced increase in 
proliferation is expressed as percentage of baseline levels, 
which was set to 100%. Even low concentrations of LTA 
(0.01 µg/ml) were capable of inducing a significant increase 
in cellular proliferation. After 24 and 48 h of stimulation, 
all LTA concentrations induced increases in proliferation 
by ~25 to 35% of baseline levels. After 72  h of stimula-
tion, increased proliferation was still observed when low 
(0.01  µg/ml) concentrations of LTA were used, whereas 
stimulation with 1  µg/ml LTA over this time period was 
ineffective. The most prominent increase in cellular prolif-
eration was observed after stimulation with 0.1 µg/ml LTA 
for 48 h (increase by 35.36% ± 1.25% of baseline levels).
Table 1  (a) Basal expression of TLR-2 mRNA in A549 and H226 cells (n = 4), (b) regulation of TLR-2 mRNA expression upon stimulation 
with LTA in A549 and H226 cells, n = 4
* p < 0.05 vs control
(a) A549, Ct H226, Ct
TLR-2 mRNA 27.69 ± 0.43 27.70 ± 0.39
PBGD mRNA 21.41± 0.18 21.94 ± 0.13
(b) TLR-2mRNA A549, fold-regulation H226, fold regulation
Control 1 1
LTA 0.1 µg/ml 1.99 ± 0.39* 0,90 ± 0.20
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LTA failed to induce any pro-proliferative activ-
ity of A549 cells when applied at lower concentra-
tions than 0.01  µg/ml: After 24  h, proliferation rates 
were 105.1 ± 2.7% of baseline upon stimulation with 
0.001  µg/ml LTA and 103.4 ± 2.9% after stimulation 
with 0.0001  µg/ml LTA (n = 5). Also after longer incu-
bation periods with 0.001  µg/ml LTA and below, no 
significant pro-proliferative effect of LTA was observed 
(e.g. after 48h, proliferation induced by 0.001 µg/ml LTA 
was 105.5 ± 0.7 and 99.2 ± 1.9% of baseline levels when 
0.0001 µg/ml LTA were used, respectively, n = 5).
The assessment of metabolic activity, as quantified 
by MTS assay, showed a comparable pro-proliferative 
effect of LTA on A549 cells (Fig. 1b). MTS activity was 
expressed as percentage of baseline levels, which was set 
to 100%. After 6 h of incubation a significant increase in 
MTS activity, was noted after stimulation with 0.01 µg/ml 
LTA. After longer incubation periods of 24 and 48 h, all 
LTA concentrations increased metabolic activity of A549 
cells by ~20 to 25% of baseline levels. Just as observed 
by automatic cell counting, the most prominent increase 
in MTS activity of A549 cells was noted after stimulation 
by 0.1  µg/ml LTA for 48  h (increase by 26.9 ± 1.8% of 
baseline levels).
LTA induces a time- and dose-dependent release 
of IL-8 in a TLR-2-dependent manner
When supernatants of LTA-activated A549 cells were 
analyzed for IL-8 release by ELISA, a dose-dependent 
release of this chemokine was noted upon stimulation 
with LTA (Fig.  2). IL-8 release was analyzed after 24, 
48, and 72 h, and was expressed as ΔIL-8 versus baseline 
secretion at indicated time points. Baseline levels of IL-8 
liberated from sham-stimulated A549 cells were 53, 98 
and 83 pg/ml after 24, 48 and 72 h respectively, and were 
increased by 117, 129 and 214  pg/ml upon stimulation 
with 1 µg/ml LTA. In parallel, IL-8 mRNA was upregu-
lated 3.50-fold in response to stimulation with 0.01, 3.54-
fold upon stimulation with 0.1  µg/ml, and 11.56-fold in 
response to 1 µg/ml LTA after 24 h as compared to sham-
incubated cells.
When ligation of TLR-2 was blocked by neutraliz-
ing antibodies, IL-8 release in response to 1 µg/ml LTA 
was strongly attenuated, as depicted for a stimulation 
period for 48 h in Fig. 3. In contrast, neutralizing TLR-4 
had no inhibitory effect on LTA-induced release of this 
chemokine.
Fig. 1  Time-dependent induction of A549 proliferation and MTS 
activity by LTA. a A549 cells were incubated with various concen-
trations of LTA from S. aureus or sham-incubated (control). A549 
proliferation was assessed by automatic cell counting. The horizon-
tal dotted line indicates the baseline proliferation of sham-incubated 
cells, which was set to 100%. All data are expressed as percentage 
of baseline proliferation. Means ± SEM of at least seven independ-
ent experiments are given. Values marked with an asterisk differ 
significantly from controls (p < 0.05). b A549 cells were incubated 
with various concentrations of LTA from S. aureus or sham-incu-
bated (control). Metabolic activity of A549 cells was quantified by 
MTS assay. The horizontal dotted line indicates the baseline prolif-
eration of sham-incubated cells, which was set to 100%. All data are 
expressed as percentage of baseline proliferation. Means ± SEM of at 
least seven independent experiments are given. Values marked with 
an asterisk differ significantly from controls (p < 0.05)
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Mechanisms of LTA-induced A549 cell proliferation 
in vitro
In order to determine the mechanism of LTA-stimulated 
A549 cellular proliferation, TLR-2, TLR-4 and IL-8 were 
blocked by antibodies under different experimental con-
ditions. Concretely, stimulation with 0.1 and 1  µg/ml 
LTA was performed in the absence or presence of these 
neutralizing antibodies for 24 and 48 h, and cellular pro-
liferation was assessed by automatic cell counting. Stim-
ulation of cellular proliferation induced by 0.1 and 1 µg/
ml LTA for 24h was inhibited by interference with TLR-
2, whereas inhibition of TLR-4 had no effect (Fig. 4a/c). 
This inhibitory effect was still reproducible when stim-
ulation with LTA (0.1 and 1  µg/ml) was performed for 
48  h (Fig.  4b/d). Most interestingly, neutralization of 
endogenously produced IL-8 abolished LTA-induced 
proliferation of A549 cells under all experimental condi-
tions (Fig.  4 a–d). Exogenous IL-8 (2  ng/ml) induced a 
pro-proliferative response of 126.8 ± 3.7% (n = 6) as com-
pared to baseline levels (100%), which was not blocked 
by the presence of anti-TLR2-antibodies (increase in pro-
liferation to 125.7 ± 3.8%, n = 6), nor did the TLR-2 anti-
bodies affect baseline proliferation (baseline proliferation 
in the presence of TLR-2 antibodies was 100.7 ± 2.2%, 
n = 6).
The pro-proliferative effects of LTA can be reproduced 
for the NSCLC squamous carcinoma cell line H226
Finally, we tried to reproduce the pro-proliferative effect 
of LTA in a NSCLC cell line of squamous cell origin. 
For this purpose, H226 monolayers were stimulated with 
increasing concentrations of highly purified LTA (0.01, 
0.1, and 1 µg/ml) for various time periods (24, 48, 72 h). 
As assessed by automatic cell counting, LTA induced 
proliferation of H226 cells approximately to the same 
extent as previously observed in A549 cells. A strong 
proliferative response in H226 cells was elicited even 
by the low LTA-concentration of 0.01  µg/ml. Similar to 
A549 cells, lower concentrations of LTA did not exert 
any pro-proliferative effect (data not given). The pro-
proliferative effect of LTA was observed over the whole 
incubation period of 72  h. In parallel, MTS activity 
was enhanced upon stimulation with LTA, with an early 
response after 6 h of stimulation and an ongoing increase 
of MTS activity until 48 h (Fig. 5a/b).
Fig. 2  Release of IL-8 from A549 cells in response to LTA. A549 
cells were either sham-incubated (control) or exposed to the given 
concentrations of LTA. At indicated time points, cell superna-
tants were collected and analyzed for IL-8 by ELISA technique. 
IL-8 release is given as ΔIL-8, which is the difference between 
IL-8 released from LTA-stimulated and sham-incubated cells (indi-
cated by the horizontal dotted line). ΔIL-8 is expressed in pg/ml. 
Means ± SEM of at least four independent experiments are given. 
Values marked with an asterisk differ significantly from controls 
(p < 0.05)
Fig. 3  Effect of TLR-2/-4 antagonists on LTA-induced synthesis of 
IL-8. A549 cells were either sham-incubated (control) or exposed to 
1 µg/ml of LTA in the absence or presence of neutralizing antibod-
ies targeting TLR-2 or TLR-4 for 48 h. Release of IL-8 into the cell 
supernatants was analyzed by ELISA technique and is given as ΔIL-8 
(pg/ml), which was calculated by subtracting IL-8 values of sham-
incubated cells from LTA-stimulated cells. Data are expressed as 
means ± SEM of at least six independent experiments. Values marked 
with an asterisk differ significantly from controls (p < 0.05)
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Discussion
Pulmonary bacterial infections are frequently found in 
advanced stages of lung cancer and may contribute to the 
progression of this disease [2, 3]. In this context, bacterial 
pathogenicity factors may play a decisive role by stimu-
lating cancer cell growth. While a strong pro-proliferative 
effect has been described for LPS, the endotoxin of Gram-
negative bacteria, in lung, liver, ovarian, gastric and breast 
cancer [28, 29, 37–40], less is known about the pathogenic-
ity factors of Gram-positive germs in this context.
In the present study, we observed that highly purified 
LTA from S. aureus induces proliferation in the lung adeno-
carcinoma cell line A549. The increase in cellular prolifer-
ation assessed by automatic cell counting was paralleled by 
an enhanced MTS activity. The increase in metabolic activ-
ity was clearly related to the increase in cell numbers thus 
confirming the observation that turnover of MTS is directly 
proportional to the numbers of viable cells in culture [41]. 
Notably, in both assays, LTA induced an increase in prolif-
eration by ~30%, thus approaching or even exceeding the 
biological activity of other well-known endo- or exogenous 
proliferative agents such as IL-8 [17] or benzo[a]pyrene 
[42]. The pro-proliferative effect of LTA was not restricted 
to A549 cells but could be reproduced in a NSCLC line of 
squamous cell origin, suggesting a pathogenic role of LTA 
in lung cancer progression in general.
The pro-proliferative effects were clearly caused by LTA 
and not by contaminating LPS. First, we used highly puri-
fied LTA prepared according to the method of Morath et al. 
[43]. Second, compared to LPS much lower concentra-
tions of LTA (0.01 µg/ml) were sufficient to stimulate cel-
lular proliferation of A549 cells [28, 29]. Third, inhibition 
of TLR-4 by an antibody that effectively inhibited LPS-
induced cellular responses [44, 45], did not affect the LTA-
induced proliferation of the NSCLC cell line. And fourth, 
the LPS-induced pro-proliferative response in A549 cells 
displayed different kinetics compared to LPS, with a maxi-
mum response at 24 h and a rapid decline thereafter [28].
However, we cannot completely rule out that contamina-
tion with staphylococcal Lpp may have contributed, at least 
in part, to the biological activity of the LTA preparation 
used here. Despite broad evidence of the immunostimula-
tory potency of LTA [reviewed in 46], Lpp display some 
immune activation functions by ligation of TLR-2 [26], and 
some recent reports suggested that the immunostimulatory 
Fig. 4  Mechanisms of LTA-induced proliferation of A549 cells. 
A549 cells were either sham-incubated (control) or exposed to 0.1 
(a/b) or 1 µg/ml (c/d) of LTA for 24 or 48 h in the absence or pres-
ence of neutralizing antibodies targeting TLR-2, TLR-4 or IL-8. 
A549 proliferation was assessed by automatic cell counting. All data 
are expressed as percentage of baseline proliferation of sham-incu-
bated cells, which was set to 100%. Means  ±  SEM of at least four 
independent experiments are given. Values marked with an asterisk 
differ significantly from controls (p < 0.05)
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effects of LTA were, at least in part, mediated by contami-
nating Lpp [47, 48]. However, synthetic LTA has been 
demonstrated to activate cytokine synthesis [49] and in 
a recent report performed in full blood, it has also been 
shown that binding of LTA to TLR-2 is a prerequisite to 
elicit cytokine synthesis [50]. Thus, we believe that LTA is 
a potent activator of cellular inflammatory reactions.
It is noteworthy that, in contrast to LPS-induced stimu-
lation [28, 29], LTA-mediated cellular proliferation dis-
played no clear dose-dependency. LTA-concentrations 
from 0.01 to 1 µg/ml induced proliferative responses. This 
observation is reminiscent of the “all or nothing” principle 
in human biology, which means that a cellular reaction is 
initiated as soon as a certain “threshold” concentration of 
receptor saturation is reached [51]. Therefore, one could 
speculate that TLR-2 receptors are “saturated” by 0.01 µg/
ml LTA, as lower concentrations of LTA failed to induce 
any significant pro-proliferative response. The absence of 
a clear dose-dependency in LTA-induced cellular prolifer-
ation corresponds well to the studies of Rezania et  al., in 
which increased metabolic activity of human prostate can-
cer cell lines over a wide range of LTA-concentrations dis-
played no dose-dependency [10].
When higher concentrations of LTA (1  µg/ml) were 
used, cellular proliferation could not be further enhanced 
and was even reduced to baseline levels after the longest 
incubation period. This may be explained to the previously 
reported pro-apoptotic effects of LTA in high concentra-
tions which may counteract the pro-proliferative effects of 
LTA at least in higher concentrations [52].
In our experimental setup LTA induced proliferation 
of A549 cells by a sequence of TLR-2 ligation, and sub-
sequent activation of IL-8 synthesis. As a prerequisite for 
specific interaction with LTA, constitutive expression of 
TLR-2 mRNA was proven in both cell lines by real-time 
RT-PCR. Interestingly, LTA even induced up-regulation of 
TLR-2 mRNA in A549 cells. The relevance of TLR-2-ex-
pression was clearly demonstrated by the use of function 
blocking antibodies to TLR-2 and TLR-4. While LTA-
induced release of IL-8 was abrogated in the presence of 
a TLR-2-antibody, blocking of TLR-4 did not affect IL-8 
secretion in response to LTA. The specificity of the TLR-2 
antibody was proven by the fact that it did not affect base-
line or IL-8 induced proliferation of A549 cells. The TLR-
2-dependency of LTA-induced proliferation is in line with 
previous studies which demonstrated that LTA-induced cel-
lular responses proceed via TLR-2 and further down-stream 
signaling involving pathway-specific TRAFs, activation of 
NF-κB and subsequent cytokine synthesis [8, 9, 53]. Sup-
porting our findings, it has recently been demonstrated that 
TLR-2 activation is also operative in human gastric and 
breast cancer [54].
Clearly, biological activity of IL-8 was a prerequisite 
for A549 cell proliferation in our study. When IL-8 was 
Fig. 5  Time-dependent increase in H226 proliferation and MTS 
activity by LTA. H226 cells were incubated with various concentra-
tions of LTA from S. aureus or sham-incubation was performed (con-
trol). H226 proliferation was assessed by automatic cell counting (a) 
and metabolic activity was quantified by MTS assay (b). The horizon-
tal dotted line indicates the baseline proliferation (a) and MTS activ-
ity (b) of sham-incubated cells which was set to 100%. All data are 
expressed as percentage of baseline proliferation. Means ± SEM of at 
least four independent experiments are given. Values marked with an 
asterisk differ significantly from controls (p < 0.05)
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inhibited by a neutralizing antibody proliferation of A549 
cells in response to LTA was completely abolished. The 
observation that in the low concentration of LTA (0.01 µg/
ml) no significant amounts of IL-8 were detected, does 
not stand against this mechanism, as there was still a trend 
towards elevated IL-8 levels. Moreover, IL-8 mRNA was 
elevated nearly to the same extent whether 0.01 or 0.1 µg/
ml LTA were used. We assume that IL-8 is liberated from 
A549 cells and activates adjacent A549 cells in an auto- or 
paracrine way without necessarily reaching significant con-
centrations in the cell supernatants under all experimental 
conditions.
Auto- and/or paracrine activation of A549 proliferation 
by IL-8 correspond well to the in-vitro-studies of Luppi 
et  al., which demonstrated that exogenously added IL-8 
stimulates proliferation in the NSCLC cell lines [55]. In 
line with these results, we demonstrated that addition of 
exogenous IL-8 stimulated A549 proliferation. Although 
we did not address the exact signaling events in our study, 
one mechanism of autocrine cell activation may be direct 
stimulation of the CXCR receptor type 1, which has been 
shown to be the decisive receptor subtype mediating pro-
liferative responses upon stimulation with IL-8 in A549 
cells [56]. Alternatively, IL-8 may activate NSCLC growth 
by trans-activation of EGFR, one of the key “drivers” of 
NSCLC, especially when activating mutations are found 
[57]. The capacity of IL-8 to transactivate EGFR has not 
only been shown in A549 cells [55], but also in gastric 
epithelial and endothelial cells [58, 59]. Besides its direct 
effect of tumor cell activation, IL-8 is a potent pro-angio-
genic factor in NSCLC [18, 19], which may be of further 
relevance in lung cancer patients.
In conclusion, this is the first study which demonstrates 
that purified LTA of S. aureus effectively induces growth of 
NSCLC cell lines of adeno- and squamous cell carcinoma 
origin. These effects are mediated by ligation of TLR-2, 
and IL-8 was identified as a decisive endogenous mediator 
activating tumor cell growth. Thus, infections with Gram-
positive bacteria may directly contribute to tumor growth 
in lung cancer.
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